GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (OTCPK:CZMWF) » Definitions » Cash-to-Debt

Carl Zeiss Meditec AG (Carl Zeiss Meditec AG) Cash-to-Debt

: N/A (As of Dec. 2023)
View and export this data going back to . Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Carl Zeiss Meditec AG's cash to debt ratio for the quarter that ended in Dec. 2023 was N/A.

The historical rank and industry rank for Carl Zeiss Meditec AG's Cash-to-Debt or its related term are showing as below:

CZMWF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06   Med: 0.85   Max: 4.37
Current: 0.07

During the past 13 years, Carl Zeiss Meditec AG's highest Cash to Debt Ratio was 4.37. The lowest was 0.06. And the median was 0.85.

CZMWF's Cash-to-Debt is ranked worse than
93.86% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 2.01 vs CZMWF: 0.07

Carl Zeiss Meditec AG Cash-to-Debt Historical Data

The historical data trend for Carl Zeiss Meditec AG's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Carl Zeiss Meditec AG Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash-to-Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.08 0.06 0.06 0.07

Carl Zeiss Meditec AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.21 N/A 0.07 N/A
Competitive Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Cash-to-Debt falls into.


Carl Zeiss Meditec AG Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Carl Zeiss Meditec AG's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=11.314 / (23.283 + 142.882)
=0.07

Carl Zeiss Meditec AG's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG  (OTCPK:CZMWF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Carl Zeiss Meditec AG Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Carl Zeiss Meditec AG's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Carl Zeiss Meditec AG (Carl Zeiss Meditec AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (OTCPK:CZMWF) » Definitions » Cash-to-Debt
Comparable Companies
XTER:GXI XTER:FIE FRA:PHH2 ISRG XPAR:EL BDX TSE:7741 XSWX:ALC OCSE:COLO B RMD WST XPAR:DIM TSE:4543 XSWX:STMN BAX COO HOLX TSE:7733 TSE:6869 TFX
Traded in Other Exchanges
CZMWY:USA 1AFX:Italy AFXd:UK 0DHC:UK AFX:Germany AFX:Austria
Address
Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Website
https://www.zeiss.com
Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.